Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novaferon in mild COVID-19
NCT05172037Phase 3Unknown
- Sponsor
- Genova
- Start
- Oct 2021
- Primary completion
- Mar 2022
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Novaferon with Placebo (2 arms). Primary endpoint: Rate of severe conditions with Score 3 or more serious on a seven-point ordinal scale. Status: unknown.
02
Drugs
novaferon
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05172037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05172037.